Compare CXAI & GDTC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CXAI | GDTC |
|---|---|---|
| Founded | N/A | 2018 |
| Country | United States | Singapore |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 27.8M | 10.4M |
| IPO Year | 2020 | 2021 |
| Metric | CXAI | GDTC |
|---|---|---|
| Price | $2.16 | $0.86 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 87.1K | 13.3K |
| Earning Date | 11-11-2026 | 04-24-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | ★ $4,583,000.00 | N/A |
| Revenue This Year | $74.56 | N/A |
| Revenue Next Year | $87.50 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.09 | $0.68 |
| 52 Week High | $4.88 | $3.68 |
| Indicator | CXAI | GDTC |
|---|---|---|
| Relative Strength Index (RSI) | 37.81 | 46.28 |
| Support Level | $0.16 | $0.74 |
| Resistance Level | $4.88 | $1.05 |
| Average True Range (ATR) | 0.18 | 0.08 |
| MACD | -0.10 | -0.00 |
| Stochastic Oscillator | 9.26 | 37.09 |
CXApp Inc is a provider of AI-powered employee experience solutions, delivering enterprise-grade software that enhances workplace engagement, productivity, and operational efficiency. Its cloud-based, mobile-first platform integrates artificial intelligence, automation, and real-time analytics to streamline workplace interactions across people, spaces, and technology. The company's flagship product, the CXAI Platform, provides a comprehensive suite of tools designed to empower employees and enable organizations to create smarter workplaces. The product's key components include CXAI Apps, CXAI BTS, Agentic AI Capabilities, and CXAI-VU. The company generates the majority of its revenue from Licenses.
CytoMed Therapeutics Ltd is a pre-clinical biopharmaceutical company focused on harnessing its proprietary technologies to create novel cell-based immunotherapies for the treatment of human cancers. The company's segment include: the business of innate immune cell-based immunotherapy, pluripotent stem cell-based therapy and undertaking the research and development of immune cell and stem cell-based therapy; and the business of processing and banking of cells including cord blood stem cells, research and development on cord blood derived cell-based therapy. Geographically, the company operates in Singapore and Malaysia which is the majority revenue generator.